Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
PCRX-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years--
BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024. The company also repurchased 2.0 million shares of its common stock during the fourth quarter.
PharmaCorp to Acquire Two Pharmacies in Western Canada
PCRX(NASDAQ:PCRX) SASKATOON, Saskatchewan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into definitive share purchase agreements, each dated August 29, 2025 (the “Agreements”), to acquire from the same arm’s length vendors (the “Vendors”) a 100% interest in two PharmaChoice Canada bannered pharmacies located in Western Canada, one of which includes the associated lands and building (the “Acquisitions”).
PharmaCorp Rx Inc. Reports Q2 2025 Financial Results
PCRXSASKATOON, Saskatchewan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a growing national platform for pharmacist-led community pharmacy ownership, today reported its financial results for the three and six months ended June 30, 2025.
PharmaCorp Rx Inc. Announces New Credit Facilities With CIBC and Unveils Pharmacist Co-Ownership Financing Initiative
PCRXSASKATOON, Saskatchewan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a credit agreement with Canadian Imperial Bank of Commerce (“CIBC”) providing the Corporation with up to $20,500,000 of committed credit facilities (the “Credit Facilities”), plus a $10,000,000 accordion feature and a $1,000,000 Visa credit facility. The Credit Facilities will support PharmaCorp’s acquisition strategy and the expansion of its acquisition and operating platforms.
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
PCRXNEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ:PCRX) on behalf of long-term stockholders following a class action complaint that was filed against Pacira on June 16, 2025 with a Class Period from August 2, 2023 – August 8, 2024. Our investigation concerns whether the board of directors of Pacira have breached their fiduciary duties to the company.
Pacira BioSciences Announces Phase 1 Data Showing Single Injection Of Gene Therapy PCRX-201 Provides Sustained Pain, Stiffness, And Function Improvement In Knee Osteoarthritis Patients For Up To 3-Years
PCRXPacira Biosciences: New Preliminary Data Suggests Clinical Immunogenicity Does Not Reduce Sustained Improvements In Knee Pain, Stiffness And Function Provided By Gene Therapy Candidate, PCRX-201
PCRXWhere Pacira BioSciences Stands With Analysts
PCRXNeedham Maintains Buy on Pacira BioSciences, Lowers Price Target to $30
PCRXPacira BioSciences Affirms FY2025 Sales Guidance of $725.00M-$765.00M vs $752.21M Est
PCRXPacira BioSciences Q1 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $168.92M Miss $176.03M Estimate
PCRXPreview: Pacira BioSciences's Earnings
PCRXPacira BioSciences Announces It Will Present 3-Year Safety And Efficacy Data of PCRX-201 Following Single Intra-Articular Injection For Moderate-to-Severe Knee Osteoarthritis At 2025 European Alliance Of Associations For Rheumatology June 11-14 2025 In Ba
PCRXPacira BioSciences To Present Findings From Phase 1 Study Of PCRX-201 And Its Implications For Dosing Strategy In Knee Osteoarthritis At ASGCT Annual Meeting
PCRXPacira BioSciences Announces 2-Yr Data On PCRX-201 Gene Therapy Demonstrating Sustained Knee Pain Relief
PCRXPacira BioSciences To Present 104-Week Data Of PCRX-201 For Patients With Mild To Severe Osteoarthritis Of Knee
PCRXPacira BioSciences Announces $300M Share Repurchase Program
PCRXPacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
PCRXPacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no earlier than 2039.
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences
PCRXNeedham Reiterates Buy on Pacira BioSciences, Maintains $32 Price Target
PCRXHC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $65
PCRXPacira BioSciences Settles Litigations With Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., And eVenus Pharmaceuticals Laboratories Related To Patents For EXPAREL
PCRXPacira BioSciences Announces Dosing Of First Patient In Phase 2 Study Assessing Safety And Efficacy Of PCRX-201 For Knee Osteoarthritis Treatment
PCRXBarclays Maintains Overweight on Pacira BioSciences, Raises Price Target to $24
PCRXA Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
PCRXNeedham Maintains Buy on Pacira BioSciences, Raises Price Target to $32
PCRXHC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $70
PCRXPacira BioSciences Acquires 81% Remaining Equity Stake Of GQ Bio For $32M
PCRXPacira BioSciences Sees FY2025 Sales $725.000M-$765.000M vs $744.10M Est
PCRXPacira BioSciences Q4 Adj $0.91 Beats $0.84 Estimate, Sales $187.25M Beat $184.36M Estimate
PCRXPenny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
PCRXVirpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.
RBC Capital Reiterates Sector Perform on Pacira BioSciences, Maintains $18 Price Target
PCRX6 Analysts Assess Pacira BioSciences: What You Need To Know
PCRXNeedham Maintains Buy on Pacira BioSciences, Raises Price Target to $30
PCRXPacira Reports Prelim. 2024 Revenue Of $710M vs $675.0M YoY; Co. Sets 2030 Goals Including More Than 3M Patients Treated Yearly
PCRXPacira Reports 104-Week Safety And Efficacy Data Following Local Administration Of PCRX-201 For Moderate To Severe Osteoarthritis Of Knee
PCRXPacira BioSciences Sees FY24 Revenue $680M-$705M Vs $692.7M Estimate
PCRXPacira BioSciences Q3 2024 Adj. EPS $0.83 Beats $0.70 Estimate, Sales $168.600M Miss $169.672M Estimate
PCRXInsights into Pacira BioSciences's Upcoming Earnings
PCRXPacira BioSciences Reports Prelim. Net Product Sales Of $59.1M For August 2022
PCRXPacira BioSciences: Q1 Earnings Insights
PCRXPacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Pacira BioSciences Q1 EPS $0.64 Misses $0.83 Estimate, Sales $158.00M Miss $159.49M Estimate
PCRXPacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know
PCRXPacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
